The Trichosporon species are yeast-like opportunistic pathogens in immunocompromised patients. Trichosporon asahii infections have been reported in pediatric bone marrow transplant (BMT) patients. However, its incidence is low in the adult literature. A 52-year-old Chinese woman who was diagnosed with acute myeloid leukemia received induction chemotherapy and underwent allogenic bone marrow transplant, which was complicated by a relapse and required salvage chemotherapy. She developed persistent non-neutropenic fever secondary to presumed hepatosplenic candidiasis. Antifungal therapy with fluconazole and anidulafungin was administered. She remained febrile and tender dusky nodules appeared over all the four limbs. Histopathological examination and fungal culture identified T. asahii. Oral voriconazole was initiated with complete resolution of her lesions. The Trichosporon species is a frequently isolated yeast species from cancer patients. Voriconazole has become the first choice agent against Trichosporon. We highlight the increased awareness and clinical suspicion required for diagnosis and subsequent management in similar adult patients.
Introduction
The Trichosporon species are yeast-like organisms which predominate in temperate areas. [1] Comprising part of the gastrointestinal and oral cavity microbiota, they also colonize the respiratory tract and skin and have been recognized as an emerging opportunistic pathogen in immunocompromised patients. [2] Pediatric cases describing Trichosporon asahii infection after bone marrow transplant have been reported, however reports in the adult literature are low. [3] [4] [5] We describe a 52 year-old lady with refractory acute myelogenous leukemia and presumed disseminated candidiasis, who developed cutaneous T. asahii infection 86 days following bone marrow transplant, and subsequently responded well to voriconazole.
Case Report
A 52-year-old Chinese woman was diagnosed with acute myelogenous leukemia and received induction chemotherapy consisting of daunorubicin (60 mg/m 2 ) and cytarabine (100 mg/m 2 ). Three months later, she underwent allogenic bone marrow transplant (BMT), complicated by This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
For reprints contact: reprints@medknow.com persistent non-neutropenic fever. Bacterial and fungal blood cultures remained sterile and a computed tomography (CT) scan of the thorax, abdomen, and pelvis revealed microabscesses in the liver and spleen [ Figure 1a ].
In view of a positive Fungitell (1→3)-β-D-glucan Assay (321 pg/mL) with a negative serum galactomannan optical density index (0.1), a presumed diagnosis of disseminated candidiasis was made and oral fluconazole 400 mg daily was instituted. A repeat bone marrow examination was done in view of persistent neutropenia. This revealed frank relapse, and she underwent salvage chemotherapy.
Fluconazole was substituted for intravenous anidulafungin to prevent further neutropenia and thrombocytopenia post chemotherapy. She developed neutropenic fever on the second day of salvage chemotherapy (absolute neutrophil count: 0.24). Blood cultures from her peripherally inserted central catheter (PICC) port yielded Pseudomonas aeruginosa, which was adequately treated with a 2-week course of appropriate antibiotics including meropenem, gentamicin, and ciprofloxacin. 
Discussion
This clinical scenario is an approach to scattered papulonodules in an immunocompromised patient. A key consideration includes a host of disseminated deep fungal infections including histoplasmosis, cryptococcosis, penicilliosis, and coccidioidomycosis. Other diagnostic considerations included Sweet's syndrome and leukemia cutis given her medical background. Trichosporonosis should also remain on the clinician's differential list as it carries significant mortality, and impacts choice of antifungal therapy.
The Trichosporon species is the second most frequently isolated yeast species from cancer patients, after Candida. [6] The incidence of non-Candida yeast infections is increasing in light of the extensive usage of various antifungals and an increasing number and life expectancy of immunocompromised patients. Amongst the Trichosporon species, T. asahii is the most common cause of disseminated infection and has been shown to be difficult in prediction and diagnosis. [7] Disseminated trichosporonosis has a significant mortality rate of 60-70%. The predisposing factors identified in our patient include recent chemotherapy, neutropenia, indwelling central catheters, and previous BMT, although there was no presence of underlying oral mucositis.
A joint clinical guideline for the diagnosis and management of rare invasive yeast infections was recently published by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the European Confederation of Medical Mycology (ECMM), in which the optimal option to treat Trichosporon species has been established. [8] Voriconazole, the preferred antifungal agent, is recommended in Grade B strength, with level III evidence. In-vitro susceptibility and animal models have suggested that triazoles are the most effective drugs against Trichosporon infections; however, strains within a given species have variable susceptibilities. [9] On the other hand, echinocandins demonstrated high minimum inhibitory concentrations when tested against the Trichosporon species. Voriconazole has emerged as the first-choice antifungal agent while maintaining efficacy against Trichosporon with the minimum inhibitory concentration (MIC 50 ) estimated at 0.03-0.5 µg/mL in the literature. [10] This case serves to remind physicians to consider Trichosporon species in cases of breakthrough infection or treatment failure under echinocandins or amphotericin therapy. We present a rare case of adult disseminated cutaneous trichosporonosis following BMT, which was successfully treated with oral voriconazole. This report seeks to raise awareness of this condition and the appreciation of an early skin biopsy to arrive at a correct diagnosis to inform management in similar adult patients.
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